home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410n.zip
/
M94A2630.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
43 lines
Document 2630
DOCN M94A2630
TI Clinical outcome of HIV infection in children and survival due to early
treatment by Retrovir.
DT 9412
AU Rakhmanova A; Fomin Y; Chernykh M; Popova I; Voronin E; Vlasov N;
Medical Academy of Postgraduate Education, Russian Clinical; HIV-AIDS
Center, St.-Petersburg.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):260 (abstract no. PB0470). Unique
Identifier : AIDSLINE ICA10/94369945
AB OBJECTIVE: A significant part of the HIV-AIDS epidemic has resulted from
infections by the parenteral route. This route of infected has affected
270 children in Russia. The aim was to describe the outcome in
HIV-infected children and evaluate the survival dependent on the timing
of Retrovir (Wellcome) treatment. METHODS: A cohort of 103 parenterally
infected children were prospectively followed from Jan 1991 with
periodic history, physical and laboratory assessment in Russian Clinical
HIV-AIDS Center. RESULTS: In a significant proportion of parenterally
infected children the disease developed within the first 3-4 months
after the assumed time of exposure and these children experienced a more
rapid progression to clinical AIDS. The rest continue to survive for
longer periods of time. Of the 103 parenterally HIV-infected children 28
(27.2%) developed AIDS three years after infection, 14 (13.6%) children
with AIDS have died. Among HIV-infected children a broad spectrum of
serious HIV- related diseases was observed. The common were severe
Herpes simplex infection, mucocutaneous candidiasis, PCP. Less
frequently found were LIP, disseminated cytomegalovirus infection,
cryptosporidiasis, fungal infection of skin, hepatitis B. Children with
the mostly unfavorable infection course were those who didn't receive
the Retrovir treatment. CONCLUSION: Considering the progress of
HIV-infection in children with AIDS developing during three years from
the timing of parenteral infection it's recommended to begin the
Retrovir treatment on from the diagnosis determination.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY/MORTALITY/ TRANSMISSION
Child Cohort Studies Drug Administration Schedule Follow-Up Studies
Human HIV Infections/*DRUG THERAPY/MORTALITY/TRANSMISSION Prospective
Studies Russia Survival Rate Zidovudine/*ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).